CMS advises SYNLAB on the sale of synlab slovakia s.r.o. to Unilabs Group

Stuttgart – SYNLAB International GmbH, a leader in medical diagnostic services and specialty testing in Europe, has, together with its subsidiary Synlab czech s.r.o., agreed to sell all shares in synlab slovakia s.r.o. to Unilabs Group. The agreed divestment aligns with SYNLAB’s overarching strategy to densify its network by focusing on countries that offer attractive strategic perspectives for the SYNLAB Group’s further development. Completion of the transaction is subject to approval of the relevant authorities.

An international CMS team lead by Dr Christoph Lächler and Daniel Mahn provided comprehensive legal advice to SYNLAB on the entire transaction. Apart from the purchase agreement documentation, the conclusion of an additional agreement on transitional services for providing services following the completion of the transaction was a key aspect of the mandate. The CMS Germany team was supported by the local CMS Slovakia team led by Martina Gavalec in Bratislava with regard to points of contact with Slovak law. Dr Peter Macheiner, Head of Legal M&A and Procurement, at SYNLAB in Munich, acted as in-house counsel.

SYNLAB is a long-standing client of CMS and regularly relies on the expertise of the Corporate/M&A team led by Dr Christoph Lächler, most recently on the sale of parts of its Eastern European laboratory diagnostics business to Medicover Group.

SYNLAB Group is a leader in medical diagnostic services and specialty testing in Europe. The Group offers a full range of innovative and reliable medical diagnostics to patients, practising doctors, hospitals and clinics, governments, and corporates. SYNLAB operates in more than 20 countries across four continents and holds leading positions in most markets, regularly reinforcing the strength of its network through a proven acquisition strategy.

Press Contact 
presse@cms-hs.com